Accelmed Partners

Investment decisions are led by Managing Partner Uri Geiger, who co-founded the firm. He chairs the investment committee and remains closely involved in sourcing, structuring, and monitoring portfolio companies. Senior partners and operating advisors contribute to deal execution, but final authority rests with Geiger.

No. While the firm has deep roots in Israel's healthtech ecosystem and counts several Israeli-founded portfolio companies, its mandate covers North America and Europe as well. The dual-region sourcing capability is part of its structural pitch to founders and limited partners.

Accelmed targets commercial-stage healthtech businesses with regulatory clearance and initial revenue traction — generally $5 million to $30 million in revenue — where it can take a controlling stake. The firm avoids pre-revenue venture risk and instead focuses on operational scaling, market access expansion, and preparation for strategic exit.

The firm has held certain assets significantly longer than a conventional five-to-seven-year private equity hold period. When the operational trajectory justifies extended ownership, Accelmed has proven willing to work with its limited partners to extend investment horizons rather than force a premature exit.

Accelmed has participated in syndicated transactions and recapitalizations alongside strategic acquirers and co-investment partners, particularly in its earlier funds. The firm's preference, however, is to lead or control deals directly to preserve its operational playbook.